Lewis Whitney E, Hong Lingzhi, Mott Frank E, Simon George, Wu Carol C, Rinsurongkawong Waree, Lee J Jack, Lam Vincent K, Heymach John V, Zhang Jianjun, Le Xiuning
Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
JTO Clin Res Rep. 2021 Oct 9;2(11):100237. doi: 10.1016/j.jtocrr.2021.100237. eCollection 2021 Nov.
The efficacy of targeted therapies in oncogene-driven lung adenocarcinomas (LUADs) has been well established; however, the benefit for -mutant or -rearranged lung squamous cell carcinomas (LUSCs) is less known, partially owing to the rarity of the incidence.
We reviewed the database of the MD Anderson Cancer Center and identified metastatic LUSC with classic or alterations.
There were eight patients with -mutant LUSC (median age = 58 y) and six patients with LUSC (median age = 50 y) who received tyrosine kinase inhibitors (TKIs) that were identified. Of the 14 patients, 11 (79%) were females and 12 (86%) were never smokers, similar to the demographics of or LUAD. With TKI treatment, seven of eight cases of LUSC and four of six cases of LUSC achieved partial response or stable disease, but the progression-free survival was 4.9 months and 2.9 months for -mutant and -rearranged LUSC, respectively. In addition, we compared comutation profile of -mutant LUAD (The Cancer Genome Atlas, n = 46) versus LUSC (n = 19) and found that the comutation patterns are more consistent with squamous disease with a higher incidence of ( = 0.02) and or ( = 0.04) alterations.
or alterations occur in patients with LUSC, especially never-smoker females. TKI treatments render clinical benefit in disease control, but the duration was considerably truncated compared with those historically observed in LUAD.
靶向治疗在致癌基因驱动的肺腺癌（LUAD）中的疗效已得到充分证实；然而，对于携带特定突变或重排的肺鳞状细胞癌（LUSC）的益处却鲜为人知，部分原因是其发病率较低。
我们回顾了MD安德森癌症中心的数据库，并确定了具有典型特定改变的转移性LUSC。
有8例携带特定突变的LUSC患者（中位年龄 = 58岁）和6例携带特定重排的LUSC患者（中位年龄 = 50岁）接受了已确定的酪氨酸激酶抑制剂（TKI）治疗。在这14例患者中，11例（79%）为女性，12例（86%）为从不吸烟者，这与携带特定突变或重排的LUAD的人口统计学特征相似。接受TKI治疗后，8例携带特定突变的LUSC患者中有7例以及6例携带特定重排的LUSC患者中有4例达到部分缓解或疾病稳定，但携带特定突变和特定重排的LUSC的无进展生存期分别为4.9个月和2.9个月。此外，我们比较了携带特定突变的LUAD（癌症基因组图谱，n = 46）与LUSC（n = 19）的共突变谱，发现共突变模式与鳞状疾病更为一致，特定基因改变的发生率更高（P = 0.02）以及其他特定基因改变（P = 0.04）。
特定改变发生在LUSC患者中，尤其是从不吸烟的女性。TKI治疗在疾病控制方面带来了临床益处，但与历史上在LUAD中观察到的相比，持续时间明显缩短。
